{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T01:38:59Z","timestamp":1788745139704,"version":"build-2803163510"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"United Kingdom Federal, Commonwealth & Development Office"},{"name":"SHAPE"},{"name":"Rwandan government"},{"name":"Clinton Health Access Initiative"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sofosbuvir\/velpatasvir\/voxilaprevir is recommended for hepatitis C virus (HCV) retreatment in those who fail initial treatment but is unavailable in resource-limited settings. We describe a government sofosbuvir\/velpatasvir + ribavirin (SOF\/VEL + RBV) \u00d7 24 weeks retreatment program in Rwanda (November 2021\u2013October 2022). Of 231 participants, 174 were cured (75.3% intention-to-treat analysis). SOF\/VEL + RBV may be considered for HCV retreatment in resource-limited settings.<\/jats:p>","DOI":"10.1093\/cid\/ciae637","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T15:18:16Z","timestamp":1736263096000},"page":"1302-1305","source":"Crossref","is-referenced-by-count":4,"title":["Introducing Sofosbuvir\/Velpatasvir + Ribavirin as a Generic Retreatment Regimen for Hepatitis C: Evaluation of a Government Program in Rwanda"],"prefix":"10.1093","volume":"80","author":[{"given":"Janvier","family":"Serumondo","sequence":"first","affiliation":[{"name":"Rwanda Ministry of Health, Rwanda Biomedical Center , Kigali ,","place":["Rwanda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Barebwanuwe","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative , Kigali ,","place":["Rwanda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2814-8755","authenticated-orcid":false,"given":"Ephrem Daniel","family":"Sheferaw","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative , Kigali ,","place":["Rwanda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Iyonizera","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative , Kigali ,","place":["Rwanda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3669-0826","authenticated-orcid":false,"given":"Charles","family":"Berabose","sequence":"additional","affiliation":[{"name":"Rwanda Ministry of Health, Rwanda Biomedical Center , Kigali ,","place":["Rwanda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Umuraza","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative , Kigali ,","place":["Rwanda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calliope","family":"Ntuyenabo","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative , Kigali ,","place":["Rwanda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly Reine","family":"Kwizera","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative , Kigali ,","place":["Rwanda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatha","family":"Dushimiyimana","sequence":"additional","affiliation":[{"name":"Rwanda Ministry of Health, Rwanda Biomedical Center , Kigali ,","place":["Rwanda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9408-7685","authenticated-orcid":false,"given":"Justine","family":"Umutesi","sequence":"additional","affiliation":[{"name":"Rwanda Ministry of Health, Rwanda Biomedical Center , Kigali ,","place":["Rwanda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Damascene","family":"Kabakambira","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The University Teaching Hospital of Kigali , Kigali ,","place":["Rwanda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobo","family":"Buya","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative , Kigali ,","place":["Rwanda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Azania","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1939-1307","authenticated-orcid":false,"given":"Caroline E","family":"Boeke","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alida","family":"Ngwije","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative , Kigali ,","place":["Rwanda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2419-2054","authenticated-orcid":false,"given":"Christian B","family":"Ramers","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gallican","family":"Rwibasira","sequence":"additional","affiliation":[{"name":"Rwanda Ministry of Health, Rwanda Biomedical Center , Kigali ,","place":["Rwanda"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"2025071809221976600_ciae637-B1","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1080\/17474124.2018.1541237","article-title":"Direct acting antivirals failure: cause and retreatment options","volume":"12","author":"Parlati","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2025071809221976600_ciae637-B2","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourliere","year":"2017","journal-title":"N Engl J Med"},{"key":"2025071809221976600_ciae637-B3","volume-title":"Guidelines for the care and treatment of persons diagnosed with chronic HCV infection","author":"World Health Organization","year":"2018"},{"key":"2025071809221976600_ciae637-B4","volume-title":"Pharmacoeconomic review report: sofosbuvir\/velpatasvir\/voxilaprevir (vosevi): (Gilead Sciences Canada, Inc): indication: hepatitis C infection genotype 1 to 6","author":"Canadian Agency for Drugs and Technologies in Health","year":"2018"},{"key":"2025071809221976600_ciae637-B5","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N Engl J Med"},{"key":"2025071809221976600_ciae637-B6","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3350\/cmh.2019.0022","article-title":"Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure","volume":"25","author":"Parigi","year":"2019","journal-title":"Clin Mol Hepatol"},{"key":"2025071809221976600_ciae637-B7","doi-asserted-by":"crossref","first-page":"9075905","DOI":"10.1155\/2020\/9075905","article-title":"Quadruple therapy offers high SVR rates in patients with HCV genotype 4 with previous treatment failure","volume":"2020","author":"Abo-Amer","year":"2020","journal-title":"Adv Virol"},{"key":"2025071809221976600_ciae637-B8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jhep.2021.02.024","article-title":"Glecaprevir\/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings","volume":"75","author":"Martin","year":"2021","journal-title":"J Hepatol"},{"key":"2025071809221976600_ciae637-B9","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/hep.29256","article-title":"Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen","volume":"66","author":"Gane","year":"2017","journal-title":"Hepatology"},{"key":"2025071809221976600_ciae637-B10","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/jgh.15324","article-title":"Efficacy and safety of sofosbuvir\/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort","volume":"36","author":"Wong","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"2025071809221976600_ciae637-B11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/cid\/ciab461","article-title":"Retreatment of chronic hepatitis C infection: real-world regimens and outcomes from national treatment programs in three low- and middle-income countries","volume":"74","author":"Boeke","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025071809221976600_ciae637-B12","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S2468-1253(18)30118-3","article-title":"Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1","volume":"3","author":"Bourli\u00e8re","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae637\/61662850\/ciae637.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/6\/1302\/61662850\/ciae637.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/6\/1302\/61662850\/ciae637.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T13:22:22Z","timestamp":1752844942000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/80\/6\/1302\/7985542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":12,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,1,29]]},"published-print":{"date-parts":[[2025,7,18]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae637","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,15]]},"published":{"date-parts":[[2025,1,29]]}}}